CASI Pharmaceuticals Inc (NASDAQ:CASI) CFO Brian D. Coleman Buys 20,000 Shares
CASI Pharmaceuticals Inc (NASDAQ:CASI) CFO Brian D. Coleman bought 20,000 shares of the stock in a transaction on Wednesday, August 14th. The shares were bought at an average price of $2.44 per share, for a total transaction of $48,800.00.
CASI stock traded down $0.15 during midday trading on Monday, hitting $3.38. 18,767 shares of the stock were exchanged, compared to its average volume of 203,181. The stock’s 50-day moving average price is $3.15 and its 200-day moving average price is $3.20. The stock has a market cap of $331.19 million, a price-to-earnings ratio of -10.56 and a beta of 1.11. CASI Pharmaceuticals Inc has a fifty-two week low of $2.73 and a fifty-two week high of $7.15.
CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings results on Friday, August 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Analysts predict that CASI Pharmaceuticals Inc will post -0.34 EPS for the current fiscal year.
A number of research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of CASI Pharmaceuticals in a report on Thursday, May 16th. BidaskClub lowered CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, June 27th.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.
Further Reading: Dead Cat Bounce
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.